Simon Ittig, T3 Pharmaceuticals CEO (via website)
November 22, 2023 12:32 PM EST
Deals
Pharma

Boehringer ac­quires Uni­ver­si­ty of Basel spin­out for $507M to de­vel­op im­munother­a­pies

Katherine Lewin

News Reporter

Boehringer In­gel­heim has ac­quired Uni­ver­si­ty of Basel spin­out T3 Phar­ma­ceu­ti­cals for 450 mil­lion CHF ($507.4 mil­lion) in an ef­fort to ex­pand …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Black­stone se­cures $1.6B so far for new life sci­ences fund tar­get­ed at $5B+

Take­da scraps pro­grams as it rais­es full-year guid­ance 

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times